Format

Send to

Choose Destination
Int J Med Sci. 2017 Sep 4;14(11):1094-1100. doi: 10.7150/ijms.20414. eCollection 2017.

Plasma Levels of Endothelial Cell-Specific Molecule-1 as a Potential Biomarker of Oral Cancer Progression.

Yang WE1,2, Hsieh MJ2,3,4, Lin CW5,6, Kuo CY7, Yang SF1,2, Chuang CY8,9, Chen MK2,7.

Author information

1
Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
2
Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
3
Cancer Research Center, Changhua Christian Hospital, Changhua, Taiwan.
4
Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
5
Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan.
6
Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan.
7
Department of Otorhinolaryngology-Head and Neck Surgery, Changhua Christian Hospital, Changhua, Taiwan.
8
School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
9
Department of Otolaryngology, Chung Shan Medical University Hospital, Taichung, Taiwan.

Abstract

In Taiwan, oral cancer is the fourth most common cancer and the most common malignancy with a poor prognosis. Endothelial cell-specific molecule-1 (ESM-1) is secreted by vascular endothelial cells in the liver, lungs, kidneys, and gastrointestinal tract. ESM-1 expression is associated with tumor prognosis, metastasis, and angiogenesis in many cancers. However, few studies have examined the association of plasma ESM-1 levels with oral squamous cell carcinoma (OSCC) progression. We measured the plasma ESM-1 levels of 438 male OSCC patients through a commercial enzyme-linked immunosorbent assay. The Cancer Genome Atlas (TCGA) dataset was also used to analyze the ESM-1 levels in 328 OSCC patients and 33 normal tissues. Our results revealed that the plasma levels of ESM-1 in OSCC patients were significantly associated with the tumor (T) status but not with the lymph node status, metastasis, and cell differentiation. TCGA bioinformatics database analysis revealed that ESM-1 expression was significantly higher in OSCC patients than in normal individuals (p < 0.05). In addition, the examination revealed similar results for the ESM-1 expression levels and pathological stage in OSCC. In conclusion, plasma ESM-1 is a novel biomarker for predicting the T status in OSCC patients.

KEYWORDS:

ESM-1; biomarker.; oral squamous cell carcinoma

PMID:
29104463
PMCID:
PMC5666540
DOI:
10.7150/ijms.20414
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Ivyspring International Publisher Icon for PubMed Central
Loading ...
Support Center